Gabather

Gabather (abbreviated form of GABA Therapeutics) focuses on the development of highly potent and selective GABAA receptor modulators targeting the principal inhibitory neurotransmitter in the mammalian brain, gamma aminobutyric acid (GABA). Our drug development candidates are small molecular weight compounds designed through proprietary pharmacophore modelling. Our development pipeline includes candidates targeting the GABAA receptor in both preclinical and clinical development and we aim to produce novel pharmaceuticals such as antipsychotics, antidepressants, anxiolytics, analgesics and cognitive enhancers to treat CNS diseases with high unmet need.